US FDA has admitted a Second Sight Medical device that the company says could help restore vision to many blind people to its Expedited Access Pathway for swifter review of groundbreaking products.

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2017.

Australia's Bionic Vision Technologies (BVT) has raised AUS$23m ($18m) from Hong Kong-based investors, China Huarong International Holdings Ltd and State Path Capital Limited, to develop and commercialize its retinal implant device. The technology could reach the market 3-5 years from now.